(Q46407329)

English

Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily

scientific article published in July 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Richard Elion

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Calvin Cohen

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Douglas Ward

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Peter Ruane

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Roberto Ortiz

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Y Sunila Reddy

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Ramin Ebrahimi

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Damian McColl

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Brian Kearney

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Alvan Fisher

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

John Flaherty

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

BATON Study Group

12

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

publication date

1 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

213-224

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

The role of adherence to antiretroviral therapy in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Metabolic issues associated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

1 reference

https://api.crossref.org/works/10.1310%2FHCT0904-213

21 January 2018

Identifiers

10.1310/HCT0904-213

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18753116

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46407329&oldid=2143875478"